<DOC>
	<DOCNO>NCT00077961</DOCNO>
	<brief_summary>The purpose study determine optimal dose subcutaneous CAMPATH use combination rituximab patient relapse refractory , low-grade follicular , CD-20-positive , B-Cell non-Hodgkin 's Lymphoma . Safety primary objective phase I , primary objective phase II determine overall response .</brief_summary>
	<brief_title>Rituximab Plus CAMPATH Patients With Relapsed/Refractory Low-Grade Follicular , CD20-positive , B-cell NHL</brief_title>
	<detailed_description>This study conduct 2 part . Phase I involve dose escalation subcutaneous CAMPATH ( SQ ) give 3 time per week combination weekly dos rituximab ( 375mg/m2 ) maximum 8 week order determine maximum tolerate dose ( MTD ) . In Phase II patient treat SQ CAMPATH MTD plus weekly rituximab ( 375mg/m2 ) maximum 8 week primary objective define Overall Response ( OR ) combination .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>For Phase I portion study , patient must pathologically confirm diagnosis lowgrade follicular , CD20positive , Bcell , nonHodgkin 's lymphoma relapse refractory . For Phase II portion study , patient must pathologically confirm diagnosis lowgrade follicular , CD20positive , Bcell , nonHodgkin 's lymphoma ( Follicular , predominantly small cleave follicular , mixed small cleave large cell , International Working Formulation classification B C REAL classification follicular center grade 1,2 ) relapse refractory . Previously treat least one anticancer regimen NHL Measurable disease ( lesion accurately measure 2 dimension CT scan great transverse diameter &gt; /= 2cm palpable lesion diameter 2cm ) Life expectancy least 12 week WHO performance status 0 1 Adequate marrow organ function ( define protocol ) Completed major surgery , radiotherapy , chemotherapy , immunotherapy biotherapy/targeted therapy least 4 week prior study entry ( 6 week treat nitrosourea mitomycin ) . Patients must recover prior treatment toxicity Grade 1 less , exclusive alopecia . Prior combination therapy rituximab CAMPATH ; prior therapy either agent alone permit A history Tcell lymphoma Known AIDSrelated HIVpositive lymphoma For Phase II portion study ( MTD determine ) , bulky disease , ie , single mass &gt; 10cm circulate malignant cell 25,000/uL Prior autologous bone marrow stem cell transplant within 6 month study entry Prior allogeneic bone marrow transplant organ transplant Prior radiotherapy site measurable disease Medical condition require chronic use oral , highdose corticosteroid Use investigational agent within 30 day study enrollment Past history anaphylaxis follow exposure humanize monoclonal antibody Known , active , infection , include HIV positive Diagnosis another malignancy within previous five ( 5 ) year , unless probability recurrence prior malignancy &lt; 5 % . Patients curatively treat early stage squamous cell carcinoma skin , basal cell carcinoma skin , cervical intraepithelial neoplasia ( CIN ) , patient history malignant tumor past diseasefree least 5 year Active central nervous system ( CNS ) involvement lymphoma Pregnant nursing woman Any significant concurrent disease illness would , opinion investigator , compromise patient safety compliance , interfere interpretation study result Active hepatitis history prior viral hepatitis B C , positive hepatitis B serology without prior immunization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>CAMPATH</keyword>
	<keyword>alemtuzumab</keyword>
</DOC>